Thought Leader Perspective: Dr. Kenneth Anderson On The Future Of Myeloma...
Dr. Kenneth Anderson, a world-renowned myeloma specialist, physician and researcher at Dana-Farber Cancer Institute, and Kraft Family Professor at Harvard Medical School, spoke with The Myeloma Beacon...
View ArticleSean’s Burgundy Thread: How’s Your L-Spike?
I recently enjoyed having an early morning breakfast with a good friend and fellow multiple myeloma patient. Like me, he was diagnosed in his late 40s, has young children, has a challenging career, and...
View ArticleRevlimid Dosing Will Continue In MM-015 Trial
Multiple myeloma patients participating in the international MM-015 study will continue to receive Revlimid maintenance treatment, despite concern that there might be a link between such treatment and...
View ArticlePat’s Place: March Is Multiple Myeloma Awareness Month
I just returned from an event designed to help kick off multiple myeloma awareness month. I didn’t remember March was “our month” until I was getting ready for the program. In the competitive world of...
View ArticleNew Advances In Myeloma Vaccines – Part 3: Completed Clinical Trials
This article is the third in a five-part series about emerging vaccines for multiple myeloma. It describes vaccines for which clinical trials have been completed. The first article in the series...
View ArticleKyphoplasty Is More Effective Than Non-Surgical Care In Multiple Myeloma...
Results of a recent study suggest that balloon kyphoplasty provides better pain relief and more back-specific mobility one month after treatment than non-surgical care in multiple myeloma patients and...
View ArticleArnie’s Rebounding World: Induction Therapy With VAD
In my first column last month, I discussed my initial diagnosis of multiple myeloma as well as my decision to have treatment close to home and to go with a less aggressive approach. Once this decision...
View ArticleRevlimid May Be Equally Effective In Thalidomide-Resistant and...
Results of an Italian study show that patients taking Revlimid who progressed on thalidomide had similar overall response and survival rates as patients taking Revlimid who discontinued thalidomide...
View ArticlePat’s Place: Living With Survivor’s Guilt
It is an exciting time for multiple myeloma patients, researchers, and physicians. New treatment combinations and options are popping up left and right. More treatment options mean most myeloma...
View ArticleNew Advances In Myeloma Vaccines – Part 4: Ongoing Research
This article is the fourth in a five-part series about emerging vaccines for multiple myeloma. It focuses on ongoing myeloma vaccine research. The first article in the series provides an introduction...
View ArticleBeacon NewsFlashes – March 14, 2011
Aeterna Zentaris And Yakult Honsha Sign Licensing Agreement For Myeloma Drug Perifosine – Canadian drug developer Aeterna Zentaris signed a licensing agreement with the Japanese company Yakult Honsha...
View ArticleBirds In Spring: Emailing Your Doctor
I like to communicate with my doctors by email. Having spent a great deal of my career talking on the phone, the embracing of email in the work world has had a profound change in the way I do business....
View ArticlePat’s Cracked Cup: Healing Water
“Everything is a miracle. It is a miracle that one does not dissolve in one’s bath like a lump of sugar,” said Pablo Picasso. However, the bath does melt aches and pains that multiple myeloma patients...
View ArticleGenome Sequencing Reveals Clues About The Underlying Causes Of Multiple Myeloma
During a recent study, researchers sequenced the genomes of 38 multiple myeloma patients and identified a number of genetic mutations that may contribute to the onset of multiple myeloma. These...
View ArticlePat’s Place: Anger Rises Among Some Multiple Myeloma Patients As They Await A...
For some time, I have been reading about how close a number of multiple myeloma experts feel they are to turning multiple myeloma into a chronic disease. This should be good news, right? Novel therapy...
View ArticleBeacon BreakingNews – European Multiple Myeloma Researchers Issue Statement...
A group of mainly European multiple myeloma researchers has issued a statement regarding the potential link between Revlimid and secondary cancer. According to the statement, the group initially met in...
View ArticleKadian, A Little-Known Pain Drug
When my husband Dave was diagnosed with multiple myeloma in June 2008 after a compression fracture at his T8 vertebra, we were thrust into a life crisis of a cancer diagnosis. However, the more...
View ArticleBeacon NewsFlashes – March 28, 2011
Opinion: Kadian, A Little-Known Pain Drug – In the latest article published in the opinion section of the Myeloma Beacon, Lori Puente, whose husband Dave is a myeloma patient, writes about Dave’s...
View ArticleRevlimid And Secondary Cancers: An Update
There have been several additional developments in the past few weeks related to concerns about a potential link between Revlimid and secondary cancers. A group of myeloma researchers issued a joint...
View ArticleAredia Does Not Prevent Disease Progression In Smoldering Myeloma Patients
According to a recent study, the bisphosphonate Aredia reduces skeletal-related events, such as bone lesions and bone fractures, in patients with smoldering multiple myeloma; however, it does not...
View Article